Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Breyer

Showing results (11-20 of 127) with videos related to

Pageof 13
Sort By:
Expert Opinion on Drug Discovery|November 18, 2017
Novel avenues for drug discovery in diabetic kidney diseaseMatthew D Breyer, Matthias Kretzler
Kidney International|February 27, 2010
Better nephrology for mice--and manMatthew D Breyer, Zhonghua Qi
Methods in Molecular Biology (Clifton, N.J.)|January 17, 2009
Measurement of glomerular filtration rate in conscious miceZhonghua Qi, Matthew D Breyer
Kidney International|September 17, 2005
Diabetic nephropathy: big and badZhonghua Qi, Matthew D Breyer
Nature Reviews. Drug Discovery|May 28, 2016
The next generation of therapeutics for chronic kidney diseaseMatthew D Breyer, Katalin Susztak
Journal of the American Society of Nephrology : JASN|April 24, 2023
Tackling AKIRajashree Rana, Matthew D Breyer
Clinical Journal of the American Society of Nephrology : CJASN|March 21, 2020
The Use of Genomics to Drive Kidney Disease Drug Discovery and DevelopmentDermot F Reilly, Matthew D Breyer
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Update on cyclooxygenase-2 inhibitorsRaymond C Harris, Matthew D Breyer
Hypertension (Dallas, Tex. : 1979)|August 18, 2004
Hypertension and cyclooxygenase-2 inhibitors: target: the renal medullaChuan-Ming Hao, Matthew D Breyer
Kidney International|March 13, 2010
Osteopontin in diabetic nephropathy: signpost or road?Josef G Heuer, Matthew D Breyer
Pageof 13

Showing results (11-20 of 127) with videos related to

Sort By:
Pageof 13
Expert Opinion on Drug Discovery|November 18, 2017
Novel avenues for drug discovery in diabetic kidney diseaseMatthew D Breyer, Matthias Kretzler
Kidney International|February 27, 2010
Better nephrology for mice--and manMatthew D Breyer, Zhonghua Qi
Methods in Molecular Biology (Clifton, N.J.)|January 17, 2009
Measurement of glomerular filtration rate in conscious miceZhonghua Qi, Matthew D Breyer
Kidney International|September 17, 2005
Diabetic nephropathy: big and badZhonghua Qi, Matthew D Breyer
Nature Reviews. Drug Discovery|May 28, 2016
The next generation of therapeutics for chronic kidney diseaseMatthew D Breyer, Katalin Susztak
Journal of the American Society of Nephrology : JASN|April 24, 2023
Tackling AKIRajashree Rana, Matthew D Breyer
Clinical Journal of the American Society of Nephrology : CJASN|March 21, 2020
The Use of Genomics to Drive Kidney Disease Drug Discovery and DevelopmentDermot F Reilly, Matthew D Breyer
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Update on cyclooxygenase-2 inhibitorsRaymond C Harris, Matthew D Breyer
Hypertension (Dallas, Tex. : 1979)|August 18, 2004
Hypertension and cyclooxygenase-2 inhibitors: target: the renal medullaChuan-Ming Hao, Matthew D Breyer
Kidney International|March 13, 2010
Osteopontin in diabetic nephropathy: signpost or road?Josef G Heuer, Matthew D Breyer
Pageof 13